 |
|
|
| |
Comparison of the Antivirogram and PhenoSense assays to determine phenotypic susceptibility to rilpivirine in patient samples from the Phase III ECHO and THRIVE trials
|
| |
| |
Reported by Jules Levin
International Workshop on HIV & Hepatitis Virus
Drug Resistance and Curative Strategies
Sitges, Spain, 5-9 June 2012
Veerle Van Eygen,1 Laurence Rimsky,1 Gaston Picchio,2 Johan Vingerhoets1
1Janssen Infectious Diseases BVBA, Beerse, Belgium; 2Janssen Research & Development LLC, Titusville, NJ, USA
|
| |
|
|
|
|
|
